Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Indaptus Therapeutics Inc (INDP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: INDP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -58.52% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.67M USD | Price to earnings Ratio - | 1Y Target Price 8.5 |
Price to earnings Ratio - | 1Y Target Price 8.5 | ||
Volume (30-day avg) 818151 | Beta 1.11 | 52 Weeks Range 0.51 - 3.10 | Updated Date 04/1/2025 |
52 Weeks Range 0.51 - 3.10 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.61 |
Earnings Date
Report Date 2025-03-13 | When - | Estimate -0.41 | Actual -0.38 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -86.28% | Return on Equity (TTM) -187.53% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2089202 | Price to Sales(TTM) - |
Enterprise Value 2089202 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.03 | Shares Outstanding 14429200 | Shares Floating 8088024 |
Shares Outstanding 14429200 | Shares Floating 8088024 | ||
Percent Insiders 46.48 | Percent Institutions 14.2 |
Analyst Ratings
Rating 4 | Target Price 8.5 | Buy 2 | Strong Buy - |
Buy 2 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Indaptus Therapeutics Inc
Company Overview
History and Background
Indaptus Therapeutics, Inc. is a biopharmaceutical company focused on developing a novel approach to cancer immunotherapy that activates the patient's own immune system to target and destroy cancer cells. The company was founded in 2020.
Core Business Areas
- Immuno-Oncology Drug Development: Indaptus focuses on the development of immunotherapeutic products that utilize a novel platform technology to activate and expand natural killer (NK) cells to fight cancer.
Leadership and Structure
Jeffrey Wolf, MD is the CEO and chairman of the board. The company operates with a typical biotechnology organizational structure, emphasizing research and development.
Top Products and Market Share
Key Offerings
- Decoy Receptor Platform: Indaptus is developing a novel platform designed to target NK cells to treat cancer, their most advanced candidate is targeting hematological malignancies. Being in early stages of development, market share is currently 0. Major competitors would include companies with approved and developmental NK cell engagers, such as Affimed, Fate Therapeutics, and Nkarta.
Market Dynamics
Industry Overview
The immuno-oncology field is rapidly evolving with significant investments in novel approaches, including cell therapies and NK cell modulation. The market is competitive and regulatory hurdles are high.
Positioning
Indaptus is a smaller player in the immuno-oncology space, focusing on NK cell therapies. Its competitive advantage, if proven successful, lies in its novel decoy receptor platform that may offer improved efficacy and safety profiles over existing approaches.
Total Addressable Market (TAM)
The TAM for cancer immunotherapy is estimated in the hundreds of billions of dollars annually. Indaptus, being early-stage, is positioned to capture a portion of this market if its platform proves successful in clinical trials.
Upturn SWOT Analysis
Strengths
- Novel technology platform targeting NK cells
- Experienced leadership team in biotechnology
- Focus on a promising area of immuno-oncology
Weaknesses
- Early stage of development with no approved products
- Limited financial resources compared to larger pharmaceutical companies
- High risk of clinical trial failure
Opportunities
- Potential for strategic partnerships with larger pharmaceutical companies
- Expanding the application of the technology platform to other cancer types
- Favorable regulatory environment for innovative therapies
Threats
- Competition from established immuno-oncology players
- Clinical trial failures
- Changes in regulatory landscape
- Difficulty securing funding
Competitors and Market Share
Key Competitors
- AFMD
- NKarta, Inc
- Fate Therapeutics
Competitive Landscape
Indaptus's primary advantage is its proprietary technology. However, it faces strong competition from companies with more advanced clinical programs and greater financial resources.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited given the company's recent founding. Growth is focused on advancing the technology and clinical pipeline.
Future Projections: Future projections depend on clinical trial outcomes and potential partnership deals. Analyst estimates are not widely available for early-stage companies.
Recent Initiatives: Recent initiatives would include ongoing clinical trials and presentations at scientific conferences.
Summary
Indaptus Therapeutics is an early-stage immuno-oncology company with a novel NK cell targeting platform. The company's success hinges on positive clinical trial results and its ability to secure additional funding. Its biggest strengths are its technology and leadership, but it is subject to the typical early stage biotech company risks, especially clinical trial failure. The company needs to focus on managing cash and showing positive clinical trial outcomes.
Similar Companies
- AFMD
- CRIS
- NKarta, Inc
- Fate Therapeutics
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- News Articles
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Indaptus Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2015-08-04 | CEO & Director Mr. Jeffrey A. Meckler J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://indaptusrx.com |
Full time employees 7 | Website https://indaptusrx.com | ||
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.